Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-27
    E.g., 2018-06-27

Articles

14161 items
10:51 AM, May 16, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Cystic fibrosis (CF) Cell culture studies identified a phenylbenzimidamide-based RNF5 inhibitor that could help treat CF in patients harboring the ΔF508 loss-of-function mutation in CFTR. In silico screening of a small molecule library for...
10:50 AM, May 16, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV); viral infection Patient sample and mouse studies suggest inhibiting PTGDR2 or agonizing PTGDR1 could help treat RSV and other viral infections. In nasal secretions from respiratory syncytial virus (RSV)-infected infants with...
10:50 AM, May 16, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies suggest a peptide-based agent that captures Aβ42 and induces autophagy could help treat AD. The “nanosweeper” agent consists of a PEGylated GKLVFF peptide that binds Aβ42 linked...
10:50 AM, May 16, 2018  |  BC Innovations | Distillery Therapeutics

Hematology

INDICATION: Hemophilia Mouse studies suggest transplantation of hepatocytes or Factor IX-expressing hepatocyte-like cells could help treat hemophilia B, which is caused by Factor IX mutations. The hepatocyte-like cells were generated from induced pluripotent stem (iPS)...
4:34 AM, May 16, 2018  |  BC Innovations | Translation in Brief

Sickle cell strides

Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company...
11:35 AM, May 15, 2018  |  BC Innovations | Translation in Brief

Sustained delivery

Researchers from Vanderbilt University School of Medicine and Baylor College of Medicine have developed a new method for stable, long-term delivery of therapeutic proteins using antigen-specific T cells whose genomes have been modified with a...
11:32 AM, May 15, 2018  |  BC Innovations | Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A click chemistry-based method for identifying cell surface glycoproteins that bind orphan ligands could help identify new therapeutic targets. The method involves three steps: mildly oxidizing live cells to produce aldehyde...
11:29 AM, May 15, 2018  |  BC Innovations | Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Tannic acid conjugates of therapeutic proteins or viral particles could be used for cardiac-specific delivery of therapies for myocardial infarction (MI) and other heart diseases. The method involves conjugating therapeutic proteins or viral...
11:29 AM, May 15, 2018  |  BC Innovations | Distillery Techniques

Assays and screens; imaging

TECHNOLOGY: Diagnostic assays; other An ultrasound-based assay for detecting blood flow in the pancreas could help predict disease progression and monitor treatment responses in Type I diabetes. The method involves injection of a gas-filled lipid microbubble...
11:29 AM, May 15, 2018  |  BC Innovations | Distillery Techniques

Biomarkers; other

TECHNOLOGY: Gene profiling; computational models A gene profiling-based computational model could identify single-gene deletions as markers of response to therapies for high-grade serous ovarian cancer (HGSOC) patients. The model is generated by transfecting a human breast...

Pages